Jean-Philippe Empana

Jean-Philippe Empana

Auto-generated profile, based on publicly available information

Jean-Philippe Empana

Inserm, PARCC, F-75015 (M.-C.P., F.B., E.M., X.J., J.-P.E., A. Cariou), Sudden Death Expertise Centre, Université Paris Cité, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Hypertension
Verified
Journal Article
Closed access
PDF file
RBRosa Maria Bruno
Rosa Maria Bruno
PNPeter M. Nilsson
Peter M. Nilsson
GEGunnar Engström
Gunnar Engström
BWBenjamin Nilsson Wadström
Benjamin Nilsson Wadström
JEJean-Philippe Empana
Jean-Philippe Empana
SLStéphane Laurent
Stéphane Laurent
Pulse wave velocity is an established marker of early vascular aging but may also help identifying individuals with supernormal vascular aging. We tested the hypothesis that individuals with the largest difference (Δ-age) between chronological and vascular age show the lowest rate of cardiovascular events and may thus be defined as supernormal vascular aging. Vascular age was defined as the predicted age in the best fitting multivariable regression model including classical risk factors and treatment and pulse wave velocity, in a subset of the Reference Values for Arterial Stiffness Collaboration Database (n=3347). Δ-age was then calculated as chronological age minus vascular age, and the 10th and 90th percentiles were used to define early (Δ-age<−5.7 years), normal (Δ-age −5.7 to 6.8 years) and supernormal vascular aging (Δ-age>6.8 years). The risk for fatal and nonfatal cardiovascular events associated with vascular aging categories was investigated in the Malmö Diet and Cancer Study cohort (n=2642). In the Malmö Diet and Cancer Study Cohort (6.6-year follow-up, 286 events), Δ-age was significantly ( P <0.01) and inversely associated with cardiovascular events. Compared with normal vascular aging, supernormal vascular aging had lower risk (hazard ratio, 0.59 [95% CI, 0.41–0.85]), whereas early vascular aging had higher risk (hazard ratio, 2.70 [95% CI, 1.55–4.70]) of cardiovascular events, in particular coronary events. There was no significant association with all-cause mortality. This study represents the first validation of the clinical significance of the supernormal vascular aging concept, based on prospective data. Its further characterization may help discovering novel protective molecular pathways and providing preventive strategies for successful vascular aging.

1 April 2009 in Stroke
Verified
Journal Article
Closed access
JEJean-Philippe Empana
Jean-Philippe Empana
Yves DauvilliersYves Dauvilliers
Yves Dauvilliers
JDJean-François Dartigues
Jean-François Dartigues
KRKaren Ritchie
Karen Ritchie
JGJerome Gariepy
Jerome Gariepy
PDPierre Ducimetiere
Pierre Ducimetiere
Background and Purpose— Excessive daytime sleepiness, one of the most frequent sleep complaints in the elderly, may affect survival, but inconsistent results have been observed in that population so far. We therefore estimated the risk of mortality for excessive daytime sleepiness (EDS) in community-dwelling elderly participating in the Three City Study. Methods— The Three City Study is a French population-based multicenter prospective study including 9294 subjects (60% women) aged ≥65 years at recruitment between 1999 to 2001. At baseline, 8269 subjects rated EDS and nocturnal sleep complaints as never, rare, regular, and frequent in response to an administered questionnaire and provided information on medication use for sleep or anxiety. Hazard ratios (HR) of EDS (regular or frequent) for mortality over 6 years were estimated by a Cox proportional hazard model. Results— At baseline, 18.7% of the study participants had regular or frequent EDS. After 6 years of follow-up, 762 subjects had died including 260 from cancer and 196 from cardiovascular disease. EDS was associated with a significant 33% increased risk of mortality (95% CI: 1.13 to 1.61) after adjustment for age, gender, study center, body mass index, previous cardiovascular disease, Mini Mental State Examination score, and cardiovascular risk factors. Further adjustment for current use of medication for sleep and for depressive symptoms slightly diminished the HRs. EDS was equally predictive of mortality in those who snored loudly and in those who did not. EDS was related to cardiovascular mortality but not to mortality attributable to cancer. Conclusion— EDS might be independently associated with total and cardiovascular mortality in community-dwelling elderly.

18 October 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
FTFlorian Thibord
Florian Thibord
DKDerek Klarin
Derek Klarin
JBJennifer A. Brody
Jennifer A. Brody
MCMing-Huei Chen
Ming-Huei Chen
MLMichael G. Levin
Michael G. Levin
NSNicholas L. Smith
Nicholas L. Smith
Background: Venous thromboembolism (VTE) is a life-threatening vascular event with environmental and genetic determinants. Recent VTE genome-wide association studies (GWAS) meta-analyses involved nearly 30 000 VTE cases and identified up to 40 genetic loci associated with VTE risk, including loci not previously suspected to play a role in hemostasis. The aim of our research was to expand discovery of new genetic loci associated with VTE by using cross-ancestry genomic resources. Methods: We present new cross-ancestry meta-analyzed GWAS results involving up to 81 669 VTE cases from 30 studies, with replication of novel loci in independent populations and loci characterization through in silico genomic interrogations. Results: In our genetic discovery effort that included 55 330 participants with VTE (47 822 European, 6320 African, and 1188 Hispanic ancestry), we identified 48 novel associations, of which 34 were replicated after correction for multiple testing. In our combined discovery-replication analysis (81 669 VTE participants) and ancestry-stratified meta-analyses (European, African, and Hispanic), we identified another 44 novel associations, which are new candidate VTE-associated loci requiring replication. In total, across all GWAS meta-analyses, we identified 135 independent genomic loci significantly associated with VTE risk. A genetic risk score of the significantly associated loci in Europeans identified a 6-fold increase in risk for those in the top 1% of scores compared with those with average scores. We also identified 31 novel transcript associations in transcriptome-wide association studies and 8 novel candidate genes with protein quantitative-trait locus Mendelian randomization analyses. In silico interrogations of hemostasis and hematology traits and a large phenome-wide association analysis of the 135 GWAS loci provided insights to biological pathways contributing to VTE, with some loci contributing to VTE through well-characterized coagulation pathways and others providing new data on the role of hematology traits, particularly platelet function. Many of the replicated loci are outside of known or currently hypothesized pathways to thrombosis. Conclusions: Our cross-ancestry GWAS meta-analyses identified new loci associated with VTE. These findings highlight new pathways to thrombosis and provide novel molecules that may be useful in the development of improved antithrombosis treatments.

1 October 2010 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
JEJean-Philippe Empana
Jean-Philippe Empana
XJXavier Jouven
Xavier Jouven
FCFlorence Canouï‐Poitrine
Florence Canouï‐Poitrine
GLGerald Luc
Gerald Luc
MTMuriel Tafflet
Muriel Tafflet
PDPierre Ducimetiere
Pierre Ducimetiere
Objective— To examine prospectively the association of high-sensitivity C-reactive protein, interleukin 6, and fibrinogen with sudden death in asymptomatic European men. Methods and Results— Among the 9771 men from the Etude PRospective de l’Infarctus du Myocarde (PRIME) Study, 664 had a first coronary heart disease over 10 years, including 50 sudden deaths, 34 nonsudden coronary deaths, and 580 nonfatal coronary heart disease events. For each outcome, 2 matched controls, who were free of coronary heart disease at the index date, were randomly selected from the initial cohort (nested case control study design). There was a 3-fold increased risk (95% CI, 1.20 to 7.81) of sudden death between the upper and the lower third of interleukin 6 after adjustment for baseline confounders in conditional logistic regression analysis. Neither high-sensitivity C-reactive protein (hazard ratio third versus first tertile =1.27; 95% CI, 0.51 to 3.17) nor fibrinogen (hazard ratio third versus first tertile =1.90; 95% CI, 0.76 to 4.75) was associated with sudden death. For comparison, there was a 6-fold increased risk of nonsudden coronary death from the highest compared with the lowest tertile of fibrinogen and a trend toward an association with higher C-reactive protein and higher interleukin 6. All 3 inflammatory biomarkers were moderately, but significantly, associated with nonfatal coronary heart disease. Conclusion— Interleukin 6, but not high-sensitivity C-reactive protein or fibrinogen, is an independent predictor of sudden death in asymptomatic European men.

3 March 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SGSophie Garnier
Sophie Garnier
MHMagdalena Harakalova
Magdalena Harakalova
SWStefan Weiss
Stefan Weiss
MMMichal Mokry
Michal Mokry
VRVera Regitz-Zagrosek
Vera Regitz-Zagrosek
PCPhilippe Charron
Philippe Charron
Our objective was to better understand the genetic bases of dilated cardiomyopathy (DCM), a leading cause of systolic heart failure. We conducted the largest genome-wide association study performed so far in DCM, with 2719 cases and 4440 controls in the discovery population. We identified and replicated two new DCM-associated loci on chromosome 3p25.1 [lead single-nucleotide polymorphism (SNP) rs62232870, P = 8.7 × 10−11 and 7.7 × 10−4 in the discovery and replication steps, respectively] and chromosome 22q11.23 (lead SNP rs7284877, P = 3.3 × 10−8 and 1.4 × 10−3 in the discovery and replication steps, respectively), while confirming two previously identified DCM loci on chromosomes 10 and 1, BAG3 and HSPB7. A genetic risk score constructed from the number of risk alleles at these four DCM loci revealed a 3-fold increased risk of DCM for individuals with 8 risk alleles compared to individuals with 5 risk alleles (median of the referral population). In silico annotation and functional 4C-sequencing analyses on iPSC-derived cardiomyocytes identify SLC6A6 as the most likely DCM gene at the 3p25.1 locus. This gene encodes a taurine transporter whose involvement in myocardial dysfunction and DCM is supported by numerous observations in humans and animals. At the 22q11.23 locus, in silico and data mining annotations, and to a lesser extent functional analysis, strongly suggest SMARCB1 as the candidate culprit gene. This study provides a better understanding of the genetic architecture of DCM and sheds light on novel biological pathways underlying heart failure. Step 1: Through the largest genome-wide association study performed so far in dilated cardiomyopathy, we identified and replicated two new loci on chromosome 3p25.1 and 22q11.23. Step 2: Combined in silico and functional analyses at the associated loci revealed the best culprit gene at each locus: SLC6A6 (chromosome 3) and SMARCB1 (chromosome 22). The discovery of these two new players shed light on novel biological pathways and putative new therapeutic targets.

20 October 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ANAboubakari Nambiema
Aboubakari Nambiema
QLQuentin Lisan
Quentin Lisan
JVJulien Vaucher
Julien Vaucher
MPMarie-Cecile Perier
Marie-Cecile Perier
PBPierre Boutouyrie
Pierre Boutouyrie
JEJean-Philippe Empana
Jean-Philippe Empana
Background and Aims: Evidence on the link between sleep patterns and cardiovascular diseases (CVDs) in the community essentially relies on studies that investigated one single sleep pattern at one point in time. This study examined the joint effect of five sleep patterns at two time points with incident CVD events. Methods: By combining the data from two prospective studies, the Paris Prospective Study III (Paris, France) and the CoLaus|PsyCoLaus study (Lausanne, Switzerland), a healthy sleep score (HSS, range 0–5) combining five sleep patterns (early chronotype, sleep duration of 7–8 h/day, never/rarely insomnia, no sleep apnoea, and no excessive daytime sleepiness) was calculated at baseline and follow-up. Results: The study sample included 11 347 CVD-free participants aged 53–64 years (44.6% women). During a median follow-up of 8.9 years [interquartile range (IQR): 8.0–10.0], 499 first CVD events occurred (339 coronary heart disease (CHD) and 175 stroke). In multivariate Cox analysis, the risk of CVD decreased by 18% [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.76–0.89] per one-point increment in the HSS. After a median follow-up of 6.0 years (IQR: 4.0–8.0) after the second follow-up, 262 first CVD events occurred including 194 CHD and 72 stroke. After adjusting for baseline HSS and covariates, the risk of CVD decreased by 16% (HR 0.84, 95% CI 0.73–0.97) per unit higher in the follow-up HSS over 2–5 years. Conclusions: Higher HSS and HSS improvement over time are associated with a lower risk of CHD and stroke in the community.